Testosterone undecanoate injectable is a Schedule III controlled substance approved by the FDA for testosterone replacement therapy in adult males with hypogonadism. It represents the longest-acting injectable testosterone formulation available in clinical practice, requiring administration only every 10-14 weeks after an initial loading phase.
This ultra-long-acting ester differs fundamentally from weekly or bi-weekly testosterone cypionate or enanthate injections. The undecanoate side chain creates a lipophilic depot in muscle tissue that releases testosterone gradually over months rather than days, producing exceptionally stable blood levels with minimal peak-to-trough fluctuation.1
Marketed as Aveed in the United States and Nebido internationally, testosterone undecanoate requires clinic-based administration by a healthcare provider. After each injection, patients must remain under observation for 30 minutes due to a rare but serious risk of pulmonary oil microembolism (POME) — a mandatory safety protocol enforced through the FDA's Risk Evaluation and Mitigation Strategy (REMS) program.
The treatment addresses primary hypogonadism, secondary hypogonadism, and age-related testosterone decline. It provides an ideal option for men who prioritize infrequent dosing over self-administration convenience, offering the fewest injection visits of any testosterone formulation while maintaining physiologic hormone levels throughout the dosing interval.
Testosterone undecanoate injectable represents one end of the convenience-frequency spectrum in testosterone replacement therapy. For comparison, testosterone cypionate and testosterone enanthate require weekly or bi-weekly self-injections but cost substantially less. Men comfortable with home injection technique often prefer these shorter-acting esters for their lower cost and dose flexibility.
Testosterone gel formulations offer daily dosing without needles, appealing to men who prioritize non-invasive delivery. However, gels require consistent application timing, skin tolerability, and precautions to prevent transfer to partners or children — factors that drive some men toward injectable options.
Compounded testosterone creams and subcutaneous pellet implants provide additional alternatives. Pellets deliver testosterone for 3-6 months after a single insertion procedure, similar to undecanoate's extended duration but requiring a minor surgical placement. Intranasal testosterone gel offers rapid absorption and twice-daily dosing for men who want to avoid both injections and skin application.
Men considering testosterone undecanoate should compare the extended dosing interval against the mandatory clinic visits, REMS observation requirements, and higher cost. The decision often comes down to whether quarterly professional injections provide enough convenience advantage over weekly self-administration to justify the additional expense and logistical constraints.
Testosterone undecanoate functions as a prodrug that releases active testosterone through enzymatic cleavage. After intramuscular injection into the gluteus medius muscle, the compound dissolves in castor oil (Aveed) or tea seed oil (Nebido) to form an intramuscular depot. The highly lipophilic undecanoate ester prevents rapid systemic absorption, creating a reservoir that slowly releases testosterone into circulation over an extended period.2
Once in the bloodstream, endogenous esterases cleave the undecanoate side chain to release free testosterone. This testosterone acts as an agonist at androgen receptors throughout the body, mediating protein synthesis, erythropoiesis, bone mineralization, and sexual function. The hormone undergoes further conversion by 5α-reductase to dihydrotestosterone (DHT) in target tissues like the prostate and skin, where DHT exerts more potent androgenic effects.3
The cleaved undecanoate side chain is biologically inactive and undergoes β-oxidation to acetyl CoA and propionyl CoA. Testosterone itself is metabolized by hepatic cytochrome P450 enzymes — primarily CYP3A4 for hydroxylation and inactivation, and CYP19A1 for aromatization to estradiol. Conjugated metabolites are excreted predominantly through bile into feces.4
Pharmacokinetic Profile
The elimination half-life of injectable testosterone undecanoate is 33.9 days after single-dose administration in castor oil, with a mean residence time of 36.0 days.5 At steady state following repeated dosing, the effective half-life shortens to approximately 20 days due to residual depot effects and potential enzyme induction. This far exceeds testosterone enanthate's 4.5-day half-life and cypionate's 8-day half-life.
Pivotal phase III trials demonstrated that after an initial loading dose of 1000 mg followed by a second 1000 mg dose at 6 weeks, 96% of hypogonadal men achieved eugonadal testosterone levels (300-1000 ng/dL) by week 7. At steady state on a 10-week dosing schedule, mean peak concentrations reached 32 nmol/L with trough levels consistently remaining above the hypogonadal threshold.6
Bioavailability approaches 100% relative to testosterone administered intravenously, bypassing the hepatic first-pass metabolism that limits oral testosterone undecanoate formulations. The depot injection strategy produces remarkably stable testosterone concentrations throughout the 10-14 week interval, with coefficients of variation typically below 30% — compared to 60-80% variation seen with weekly cypionate injections.
Clinical Efficacy Data
A multicenter trial enrolling 154 hypogonadal men found that 88% maintained eugonadal levels at the 12-week post-dose trough measurement. Symptom improvements became evident within 3-6 weeks: 71% reported enhanced libido, 60% experienced increased energy levels, and 50% noted mood stabilization by week 12.7
Long-term extension studies tracking over 1,000 patients for up to 8 years confirmed sustained efficacy. The continuation rate reached 84%, with persistent improvements in sexual function scores (+5 points on the International Index of Erectile Function), favorable body composition changes (−2.5 kg fat mass, +2 kg lean mass), and modest bone density increases of 3-5%.8
Testosterone undecanoate follows a two-phase protocol: an initial loading period to achieve therapeutic levels rapidly, followed by maintenance dosing at extended intervals. The FDA-approved Aveed regimen starts with 750 mg administered via deep intramuscular injection into the upper outer quadrant of the gluteus medius muscle. A second 750 mg dose follows at week 4, then maintenance injections of 750 mg every 10 weeks thereafter.
The international Nebido protocol uses slightly larger doses: 1000 mg at baseline, 1000 mg at week 6, then 1000 mg every 10-14 weeks. Both protocols achieve similar steady-state pharmacokinetics after the third injection.9
| Protocol Phase | Dose & Timing | Lab Monitoring |
|---|---|---|
| Loading Phase | 750 mg IM at baseline 750 mg IM at week 4 |
Total testosterone, hematocrit, PSA at baseline Repeat at week 7 |
| Maintenance (Months 3-6) | 750 mg IM every 10 weeks | Trough testosterone at week 10 (pre-injection) Hematocrit, PSA, estradiol every 10 weeks |
| Maintenance (Month 7+) | 750 mg IM every 10 weeks (adjust interval 8-12 weeks based on troughs) |
Trough testosterone every 6 months CBC, PSA, lipid panel every 6-12 months |
| Post-Injection Observation | 30-minute mandatory clinic wait | Monitor for POME symptoms: cough, dyspnea, chest tightness |
Titration Guidelines
Dosing intervals should be individualized based on trough testosterone levels measured just before the next scheduled injection. If trough levels fall below 300 ng/dL, shorten the interval to every 8-9 weeks. If trough levels exceed 1000 ng/dL, extend to every 12 weeks. Most patients stabilize on 10-week dosing after the first year.
Special populations require protocol modifications. Men over 65 years old typically start with 10-week intervals and extend to 12 weeks only if troughs remain adequate. Obese patients (BMI >35) may need shorter intervals due to increased volume of distribution, while those with secondary hypogonadism often tolerate 12-14 week dosing.
Administration Technique
Each injection must be administered by a healthcare provider using a deep intramuscular technique. The gluteus medius muscle — located in the upper outer quadrant of the buttock — is the only approved injection site. Slow injection technique over 60-90 seconds reduces the risk of pulmonary oil microembolism. Patients remain in the clinic for 30 minutes post-injection to monitor for rare but serious adverse reactions.
The most clinically significant risk associated with testosterone undecanoate is pulmonary oil microembolism (POME), which occurs in approximately 1.6% of injections. This reaction happens when the oily depot enters small blood vessels during or immediately after injection, causing acute respiratory symptoms including cough, dyspnea, throat tightening, and chest discomfort. Most episodes resolve spontaneously within 30-60 minutes, though 0.5% require medical intervention.10
POME risk necessitates the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, which restricts testosterone undecanoate to certified healthcare settings with emergency response capability. This mandatory safety protocol has proven effective — no fatalities have been attributed to POME since the REMS implementation.
| Frequency | Mild | Moderate | Severe |
|---|---|---|---|
| Common (>5%) | Injection site soreness (12%), mild acne flare | Oily skin, increased facial/body hair growth | Elevated hematocrit requiring dose adjustment (7%) |
| Occasional (1-5%) | Mild fluid retention, transient mood changes | Gynecomastia (5%), weight gain (4%) | Hematocrit >54% requiring phlebotomy |
| Rare (<1%) | — | POME respiratory symptoms (1.6%) | Anaphylaxis (0.3%), venous thromboembolism (0.5%) |
Contraindications and Warnings
Testosterone undecanoate is absolutely contraindicated in men with prostate cancer, breast cancer, or untreated severe sleep apnea. Baseline hematocrit above 50% precludes initiation due to erythrocytosis risk. Men with uncontrolled congestive heart failure should not receive treatment, as testosterone can worsen fluid retention.
The medication suppresses endogenous testosterone production and spermatogenesis, making it inappropriate for men actively trying to conceive. Fertility typically recovers 6-18 months after discontinuation, but some men experience prolonged suppression.
Monitoring Requirements
Hematocrit monitoring is critical. Values exceeding 54% require treatment interruption until levels normalize below 50%, at which point therapy can resume with closer monitoring or interval extension. PSA levels should be checked every 6 months in men over 40, with annual digital rectal examinations. A PSA velocity exceeding 0.75 ng/mL per year or absolute value above 4.0 ng/mL triggers urology referral.
Estradiol levels occasionally rise due to aromatase conversion, particularly in men with higher body fat. Symptoms of estrogen excess — nipple tenderness, gynecomastia, emotional lability — warrant measurement and potential aromatase inhibitor co-therapy.
Testosterone undecanoate injectable is available only through certified healthcare facilities enrolled in the FDA's REMS program. This restriction means patients cannot fill prescriptions at retail pharmacies or administer injections at home. Every dose must be given in a medical office, hospital, or specialty clinic with the capability to manage acute allergic reactions and respiratory emergencies.
Prescribers must complete REMS certification training before ordering testosterone undecanoate. Patients receive educational materials about POME symptoms and sign informed consent acknowledging the 30-minute post-injection observation requirement. Most urology practices, men's health clinics, and endocrinology offices maintain REMS certification.
Cost and Insurance Coverage
Each injection of testosterone undecanoate costs $1,000-1,500 before insurance. The quarterly dosing schedule translates to approximately $4,000-6,000 annually — substantially higher than weekly cypionate injections ($600-1,200/year) or daily testosterone gels ($2,400-4,800/year).
Insurance coverage varies widely. Most major plans cover testosterone undecanoate for FDA-approved hypogonadism indications when prior authorization demonstrates documented low testosterone levels (typically two morning measurements below 300 ng/dL) and symptom criteria. Insurers often require failure or intolerance of lower-cost testosterone formulations first — a practice called step therapy.
Medicare Part D plans cover testosterone undecanoate under specialty tier formularies, typically requiring 20-33% coinsurance rather than flat copays. Out-of-pocket costs for Medicare beneficiaries range from $200-500 per injection depending on supplemental coverage.
Manufacturer copay assistance programs can reduce patient responsibility to $0-50 per injection for commercially insured patients, though Medicare and Medicaid prohibit manufacturer copay cards. Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) cover testosterone undecanoate as a qualified medical expense when prescribed for diagnosed hypogonadism.
Patient Profile
Ideal candidates for testosterone undecanoate are men with confirmed hypogonadism who value infrequent dosing above all other considerations. The quarterly injection schedule appeals particularly to busy professionals, frequent travelers, and men averse to needles who prefer the fewest possible exposures.
This formulation works well for patients who struggled with adherence to weekly self-injections or daily gel applications. The clinic-scheduled visits eliminate the "did I remember my shot?" uncertainty that undermines other protocols. Men transitioning from testosterone gels due to skin reactions or inconsistent absorption often report high satisfaction with the stability of injectable undecanoate.
Poor candidates include men requiring fertility preservation, those with needle phobia severe enough that quarterly injections cause significant distress, and patients with severe cardiovascular disease or baseline hematocrit above 48%. The REMS observation requirement also presents barriers for men with limited clinic access or inflexible work schedules.